Hikma Pharmaceuticals Plc (HKMPF) Receives Consensus Rating of “Hold” from Analysts

Hikma Pharmaceuticals Plc (OTC:HKMPF) has been given an average rating of “Hold” by the six research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company.

Several research firms recently weighed in on HKMPF. Goldman Sachs Group, Inc. (The) lowered Hikma Pharmaceuticals Plc from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 22nd. Morgan Stanley restated an “equal weight” rating on shares of Hikma Pharmaceuticals Plc in a research report on Tuesday, August 8th. ValuEngine upgraded Hikma Pharmaceuticals Plc from a “hold” rating to a “buy” rating in a research report on Thursday, July 27th. Finally, Jefferies Group LLC upgraded Hikma Pharmaceuticals Plc from an “underperform” rating to a “hold” rating in a research report on Monday, August 21st.

COPYRIGHT VIOLATION WARNING: This piece was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://ledgergazette.com/2017/10/10/hikma-pharmaceuticals-plc-hkmpf-receives-consensus-rating-of-hold-from-analysts.html.

Hikma Pharmaceuticals Plc (OTC:HKMPF) opened at 15.65 on Tuesday. Hikma Pharmaceuticals Plc has a 12 month low of $15.10 and a 12 month high of $27.50. The stock’s 50 day moving average price is $15.70 and its 200-day moving average price is $20.47. The firm has a market capitalization of $3.76 billion and a price-to-earnings ratio of 22.68.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Analyst Recommendations for Hikma Pharmaceuticals Plc (OTC:HKMPF)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply